PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components

N/AActive Not RecruitingNCT02823834

MicroPort Orthopedics Inc.121 enrolled

Overview

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

Study Type

OBSERVATIONAL

Enrollment

121

Conditions

Joint Disease

Interventions

PROFEMUR® Gladiator Plasma Femoral StemsDEVICE

THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has undergone primary THA for any of the following: * Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; * Inflammatory degenerative joint disease such as rheumatoid arthritis; or * Correction of functional deformity * Subject is implanted with the specified combination of components * Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs enrolled in the study provided: * the specified combination of components were implanted in both * all other aspects of the Inclusion/Exclusion Criteria are satisfied * enrollment does not exceed the subject count specified in the Clinical Trial Agreement * the subject agrees to a second Informed Consent document specific to the second THA. Exclusion Criteria: * Subjects implanted with a metal-on-metal articulation * Subjects implanted with non-MPO or non-Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners) at the time of their primary THA in the enrolled THA * Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery * Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol * Subjects unwilling to sign the Informed Consent document * Subjects with substance abuse issues * Subjects who are incarcerated or having pending incarceration

Locations (1)

Elbe Kliniken Buxtehude

Buxtehude, Germany

Outcomes

Primary Outcomes

Component Survivorship

The primary objective of this study is to estimate survivorship analysis of all components at specified intervals out to 10 years follow-up.

Time frame: 10 years post-operative

Secondary Outcomes

Patient functional outcomes (hip specific)

To characterize total functional scores, as assessed by Oxford Hip Scores

Time frame: 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit

Patient functional outcomes (quality of life)

To characterize total functional scores, as assessed by EQ-5D-3L scores

Time frame: 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.